Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) (NCT06881784)
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Who can join: Review the eligibility criteria below.
Location: Alabama Oncology — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (153 Sites)
Showing the first 25 of 153 sites.
- Alabama Oncology — Birmingham, Alabama
- MemorialCare Long Beach Medical Center — Long Beach, California
- Yale University, Smillow Cancer Center — New Haven, Connecticut
- Florida Cancer Specialists & Research Institute - South — Fort Myers, Florida
- BRCR Global — Plantation, Florida
- Cancer Care Centers of Breevard — Rockledge, Florida
- Florida Cancer Specialists & Research Institute - North — St. Petersburg, Florida
- Cleveland Clinic Martin North — Stuart, Florida
- Florida Cancer Specialists & Research Institute - East — West Palm Beach, Florida
- University Cancer and Blood Center — Athens, Georgia
- Piedmont Healthcare, Inc — Atlanta, Georgia
- Winship Cancer Institute — Atlanta, Georgia
- Center for Care and Discovery — Chicago, Illinois
- University of Iowa Health Care Cancer Services Quad Cities — Bettendorf, Iowa
- University of Iowa Hospitals & Clinics — Iowa City, Iowa
- University of Iowa Health Care, Mission Cancer + Blood — Waukee, Iowa
- The University of Kansas Cancer Center — Westwood, Kansas
- Johns Hopkins University of Medicine — Baltimore, Maryland
- Karmanos Cancer Institute — Detroit, Michigan
- Henry Ford Health — Detroit, Michigan
- Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri
- St. Vincent Frontier Cancer Center — Billings, Montana
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
- John Theurer Cancer Center at Hackensack UMC — Hackensack, New Jersey
- Morristown Medical Center (MMCORC) — Morristown, New Jersey
📞 Contact the Study Coordinator
Phone: (205) 803-4369
Email: Stephanie.Abercrombie@alabamaoncology.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in NSCLC (Non-small Cell Lung Cancer)
Explore by condition: All NSCLC (Non-small Cell Lung Cancer) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.